The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary
Open accessAbstract
Heart failure with preserved ejection fraction (HFpEF), a major public health problem that is rising in prevalence, is associated with high morbidity and mortality and is considered to be the greatest unmet need in cardiovascular medicine today because of a general lack of effective treatments. To address this challenging syndrome, the National Heart, Lung, and Blood Institute convened a working group made up of experts in HFpEF and novel research methodologies to discuss research gaps and to prioritize research directions over the next decade. Here, we summarize the discussion of the working group, followed by key recommendations for future research priorities. There was uniform recognition that HFpEF is a highly integrated, multiorgan, systemic disorder requiring a multipronged investigative approach in both humans and animal models to improve understanding of mechanisms and treatment of HFpEF. It was recognized that advances in the understanding of basic mechanisms and the roles of inflammation, macrovascular and microvascular dysfunction, fibrosis, and tissue remodeling are needed and ideally would be obtained from (1) improved animal models, including large animal models, which incorporate the effects of aging and associated comorbid conditions; (2) repositories of deeply phenotyped physiological data and human tissue, made accessible to researchers to enhance collaboration and research advances; and (3) novel research methods that take advantage of computational advances and multiscale modeling for the analysis of complex, high-density data across multiple domains. The working group emphasized the need for interactions among basic, translational, clinical, and epidemiological scientists and across organ systems and cell types, leveraging different areas or research focus, and between research centers. A network of collaborative centers to accelerate basic, translational, and clinical research of pathobiological mechanisms and treatment strategies in HFpEF was discussed as an example of a strategy to advance research progress. This resource would facilitate comprehensive, deep phenotyping of a multicenter HFpEF patient cohort with standardized protocols and a robust biorepository. The research priorities outlined in this document are meant to stimulate scientific advances in HFpEF by providing a road map for future collaborative investigations among a diverse group of scientists across multiple domains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Obesity and diabetes create a pro-inflammatory state and promote endothelial and coronary microvascular dysfunction. 1,7,8”
From Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Obesity is a major risk factor for heart failure (HF) with preserved ejection fraction (HFpEF). 1,2”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.115.001593 · Cited by 3,466
Antlanger, M., Aschauer, S., Kopecky, C., Hecking, M., Kovarik, J. J., Werzowa, J. M., Mascherbauer, J., Genser, B., Säemann, M. D., & Bonderman, D. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000473868 · Cited by 2,808
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationPieske, B. M., Tschöpe, C., de Boer, R. A., Fraser, A. G., Anker, S. D., Donal, E., Edelmann, F., Fu, M. L. X., Guazzi, M., Lam, C. S. P., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz641 · Cited by 1,961
Reddy, Y. N. V., Carter, R. E., Obokata, M., Redfield, M. M., & Borlaug, B. A. (2018) · Circulation · doi:10.1161/circulationaha.118.034646 · Cited by 1,294
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction
González-López, E., Gallego‐Delgado, M., Guzzo-Merello, G., Moral, F. J. D. H.-D., Marcos, M. C., Robles, C., Bornstein, B., Salas, C., Lara‐Pezzi, E., Alonso‐Pulpón, L., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv338 · Cited by 1,176
Redfield, M. M., Chen, H. H., Borlaug, B. A., Semigran, M. J., Lee, K. L., Lewis, G. D., LeWinter, M. M., Rouleau, J. L., Bull, D. A., Mann, D. L., et al. (2013) · JAMA · doi:10.1001/jama.2013.2024 · Cited by 1,164
Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., Bonow, R. O., Huang, C.-C., & Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.114.010637 · Cited by 1,157
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–436 of 436
Liu, X., Wang, Z., Hua, C., Wu, Y., Tang, Y., Xiong, Y., Liu, J., Zhang, J., Lv, Q., Jiang, C., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15435
Targeting Adipose Tissue Function Protects Against Heart Failure with Preserved Ejection Fraction
Jousma, J., Han, Z., Park, J., Yan, G., Zhang, S., Kwon, Y., Nukala, S. B., Kandola, J., Pinho, S., Liew, C. W., et al. (2025) · Advanced Science · doi:10.1002/advs.202506106 · Cited by 1
Catalpol Alleviates HFpEF via Inhibition of the S100A8-RAGE-NOX4 Inflammatory Axis in Murine Hearts
Cao, Y., Li, S., Zhang, Y., He, M., & Shen, Y. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s552741
Shi, Y., Zhao, L., Wang, J., Liu, X., Bai, Y., Cong, H., & Li, X. (2024) · Figshare · doi:10.6084/m9.figshare.26752903
Shi, Y., Zhao, L., Wang, J., Liu, X., Bai, Y., Cong, H., & Li, X. (2024) · Figshare · doi:10.6084/m9.figshare.26752906
Shoukat, A., & Ambreen, M. (2025) · Malaysian Journal of Science and Advanced Technology · doi:10.56532/mjsat.v5i4.587
The Intersection of Heart Failure with Preserved Ejection Fraction and CKD
Krishnan, V., Khan, S. S., & Mehta, R. C. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001013
Early albumin infusion and mortality in ICU patients with HFpEF: a target trial emulation study
Wang, Z., Li, M.-L., Zhu, N.-J., Fan, T., & Zhang, Y. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-03996-x
Epigenomics and Epigenetics in Heart Failure with Preserved Ejection Fraction
Rabkin, S. W. (2026) · Heart Failure Clinics · doi:10.1016/j.hfc.2025.12.005
Long, Y. L., Hu, X., Cheng, Z., Guo, K., Pan, Z., & Wen, J. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.117781
Issaka, Y., Abdul-Kareem, H., Meyahnwi, D., Ntow, M. A., & Hahn, S. S. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.03.055 · Cited by 1
Khalil, I., Hossain, I., Sarker, P., Nur, N., Al-Badri, S. G., Akter, M. M., Halder, L., Rahman, M. T., & Kamrul-Hasan, A. B. M. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.03.009
Lan, Y., Wu, M., Zhang, S., Xie, Z., Wang, J., Guo, J., & Xiong, W. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05787-9
MARCH1 Deletion Attenuates HFpEF by Promoting Adipose Beiging
Zhu, Y. U. N. L. O. N., Fan, J., Tang, L., 周玉英, Jiang, K., Tan, D., Huang, H., Wu, M., Zeng, J. I. A. N. P. I., Yang, H. U. I., et al. (2026) · Comprehensive physiology · doi:10.1002/cph4.70141
Cerebrovascular disease: clinical, diagnostic and therapeutic approach to stroke
Erhardt, G. A., & Taborda, M. (2024) · International Journal of Neurology · doi:10.62486/ijn2024150
Li, M., Xiao, H., Hu, B., Gu, F., Li, X., Shu, C., Zhu, Z., & Li, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70881
Pradeep, A., Zubair, Z., Jia, K.-Y., Moumneh, M., Ennab, M., Khayat, O., Zayed, A. A., & Amor, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114252
Finerenone after FINEARTS-HF: evidence boundaries and implementation in heart failure with LVEF ≥40%
Feng, S., & Jin, H. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1880045
Mavraganis, G., Fragoulis, C., Georgiopoulos, G. A., Mavromoustakou, K., Dimitriadis, K. P., Aznaouridis, K. A., Chrysohoou, C. A., Stamatelopoulos, K. S., & Tsioufis, K. P. (2026) · Medicina · doi:10.3390/medicina62071222
Takino, K., Kuze, Y., Nagai, T., Hori, M., Nakazawa, Y., Nakagawa, M., Koyama, Y., & Matsuo, H. (2026) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2026.07.005
c-Myc: an emerging participant in heart failure
Wu, Y. T., Zhang, J., Liu, R., Lin, W., Wang, W., Zhao, Y. Q., Cai, Y. P., Su, H., Sun, W., Zhu, H., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1832539
Right Ventricular Strain Imaging: Present and Future
Sharma, P., Bose, A., & Kumar, B. (2026) · Indian Journal of Clinical Cardiology · doi:10.1177/26324636261464866
Brigić, L., Džubur, A., & Dervišević, L. (2026) · Cureus · doi:10.7759/cureus.113911
Zhang, Y., Xiao, X., Yan, Q., Huang, D., & Wang, W. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1726611
Ćićarić, N., Matic, S. D., Djordjević, N., Markovic, T., Stanojević-Pirković, M., Stevanović, Đ., Urakovic, N., Ivosevic, Z., Stojanović, L., Davidović, G., et al. (2026) · Biomedicines · doi:10.3390/biomedicines14081783
Khalil, I., Hossain, M. I., Akter, M. M., Wahid, F., Khalid, A. A., Promi, S. A., Sayed, M. A., Rahman, M. T., & Sarker, P. (2026) · Clinical Cardiology · doi:10.1002/clc.70441
Therapeutic Reversal of PH-HFpEF via Lung Spheroid Cell Exosomes
Cantor, H. J., Zhu, D., Li, Z., Hu, S., Popowski, K. D., Liu, M., Li, J., Mullens, N., Thompson, E., Caddell, A., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c06951
Which heart failure phenotypes benefit from GLP-1 receptor agonists?
Deng, J. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00328-x
Lyu, Y., Hou, J., Ma, I., Mostoufi, T., Jiang, Y., Yang, X., & Gao, W. D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177736
Shape Analysis of Coronary Flow Waveforms using Singular Value DecompositionPreprint
Sturgess, V. E., Schenk, N. A., Ziegele, J. W., Essajee, S. I., Tune, J. D., Rajapakse, I., Figueroa, C. A., & Beard, D. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.26.743980
Adejumo, F. A., Obielodan, O. O., Adetoye, F., & Aderinto, N. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1948320
Immunometabolic regulation of cardiac macrophages in heart failure with preserved ejection fraction
Liang, J., Su, M., Liu, R., Li, T., Qin, Z., & Wáng, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1896936
Integration of multiple perspectives to understand the left ventricular pressure–volume relationship
Tonti, G., Pedrizzetti, G., & Salustri, A. (2026) · Communications Medicine · doi:10.1038/s43856-026-01901-2
Congestive Heart Failure with Preserved Ejection Fraction
Mirrakhimov, A. E. (2026) · Springer eBooks · doi:10.1007/978-3-032-29397-8_34
Zhang, M., Guan, X., Lu, R., Yu, Z., Chen, X., Xu, J., Chen, G., Zhang, H., & Liu, Y. (2026) · Food Frontiers · doi:10.1002/fft2.70367
Cline, L. (2026) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000001370
Metadata
- Authors
- Shah, S. J., Borlaug, B. A., Kitzman, D. W., McCulloch, A. D., Blaxall, B. C., Agarwal, R., Chirinos, J. A., Collins, S., Deo, R. C., Gladwin, M. T., Granzier, H., Hummel, S. L., Kass, D. A., Redfield, M. M., Sam, F., Wang, T. J., Desvigne-Nickens, P., & Adhikari, B. B.
- Affiliations
- Northwestern University (US)
- Mayo Clinic (US)
- Wake Forest University Health Sciences (US)
- University of California San Diego (US)
- Christ Hospital (US)
- Indiana University Indianapolis (US)
- University of Pennsylvania (US)
- Vanderbilt University (US)
- Brigham and Women's Hospital (US)
- University of Pittsburgh (US)
- University of Arizona (US)
- University of Michigan (US)
- Johns Hopkins University (US)
- Boston University (US)
- National Institutes of Health (US)
- ORCID
- Venue
- Circulation
- Published
- 2020-03-24
- Volume
- 141
- Issue
- 12
- Pages
- 1001-1026
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- PMC
- PMC7101072
- OpenAlex
- W3012616651
- Cited by
- 436
- References
- 114
- Citations by year
- 2026: 53 · 2025: 74 · 2024: 74 · 2023: 67 · 2022: 99 · 2021: 49 · 2020: 19
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01AG018915, R01AG045551, R01AG058969, P30AG021332, U24AG059624)
- National Heart, Lung, and Blood Institute (R01HL128526, R61HL146390, R01HL118524, U01HL125175, R01HL127028, R01HL144657, R01HL104106, R01HL126638, U10HL110262, R01HL149423, DP2HL123228, R35HL135827, P01HL103455, R01HL117153, R01HL140731, P01HL094307, R01HL132551, U01HL125205, R01HL133695, R01HL121510, R01HL107577, R56HL136730, R01HL134321, R01HL125886, R01HL098032, T32HL110849)
- National Cancer Institute (K12CA090625)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK103056, P50DK096418)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- heart failure with preserved ejection fraction, research priorities, research gaps, animal models, inflammation, microvascular dysfunction, macrovascular dysfunction, fibrosis, tissue remodeling, biorepository, multiscale modeling, translational research
- MeSH terms
- Heart Failure, Humans, Research, Stroke Volume, United States, National Heart, Lung, and Blood Institute (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review